Drug developer ValiRx (LON:VAL) has noted evidence of potential efficacy in the phase I/II trial of its lead cancer treatment.
VAL201 is being trialled on patients with advanced or metastatic prostate cancer and other advanced solid tumours at UCH in London.
Satu Vainikka, chief executive, said: "The trial continues to proceed well and I am pleased to be able to say that, at this preliminary stage, potential efficacy has been detected at the lowest doses.”
Preliminary indications are that VAL201 is demonstrating the effects that have been seen in the pre-clinical studies, she added.
So far, there have been no significant adverse safety or tolerability effects.
Dose escalation is now underway to test further the compound’s safety and tolerability and also its efficacy.
No significant adverse effects have occurred so far in patients that have received higher doses.
ValiRx added that the trial proceeding on schedule.